A new clinical trial underway in the Lowcountry is drawing attention for its unconventional — and potentially groundbreaking ...

On December 11, the United States Patent and Trademark Office granted Atai Life Sciences N.V. a new patent for EMP-01, an ...

U.S. President Donald Trumphas signed an executive order demanding a speedy reclassification of marijuana that would ease ...

U.S. President Donald Trump has signed an executive order demanding a speedy reclassification of marijuana that would ease ...

Lipocine's PPD phase 3 study oral brexanolone hits 80% enrollment milestone: Salt Lake City Wednesday, December 17, 2025, 18:00 Hrs [IST] Lipocine Inc., a biopharmaceutical compan ...

Addressing major unmet needs in mental health with pharmacology rooted in emerging and clinically validated neuropsychiatric biology * Lead progra ...

Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to develop innovative products with effective oral delivery, today announced 80% completion of ...

Discover top biotech companies for 2026, featuring emerging stars and leaders set for major clinical and regulatory ...

Soligenix, Inc. (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical ...

President Donald Trump is expected to sign an executive order that would reclassify marijuana and ease federal restrictions ...

Second Drug Safety Monitoring Board (DSMB) meeting update planned for mid-January 2026 Topline results on track for the second quarter of 2026 SALT LAKE CITY, ...

LUMRYZ is only currently approved for the treatment of cataplexy or EDS in patients seven years of age and older with narcolepsy, and Avadel does not market, promote or offer patient support services ...